Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab.

Authors
  • Heelan, Kara1
  • Hassan, Shazia2
  • Bannon, Grace2
  • Knowles, Sandra2
  • Walsh, Scott2
  • Shear, Neil H2
  • Mittmann, Nicole2
  • 1 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ONHealth Outcomes and PharmacoEconomics (HOPE) Research Centre, Sunnybrook Research Institute, University of Toronto, Toronto, ONDivision of Clinical Pharmacology and Toxicology at Sunnybrook, Department of Medicine, University of Toronto, Toronto, ONDepartment of Pharmacology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ONInternational Centre for Health Innovation, Richard Ivey School of Business, Western University, London, ON [email protected]
  • 2 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ONHealth Outcomes and PharmacoEconomics (HOPE) Research Centre, Sunnybrook Research Institute, University of Toronto, Toronto, ONDivision of Clinical Pharmacology and Toxicology at Sunnybrook, Department of Medicine, University of Toronto, Toronto, ONDepartment of Pharmacology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ONInternational Centre for Health Innovation, Richard Ivey School of Business, Western University, London, ON.
Type
Published Article
Journal
Journal of cutaneous medicine and surgery
Publication Date
Jan 01, 2015
Volume
19
Issue
3
Pages
274–282
Identifiers
DOI: 10.2310/7750.2014.14092
PMID: 25775641
Source
Medline
License
Unknown

Abstract

Our findings suggest that RTX is effective in reducing health system resources and the costs associated with the treatment of pemphigus and pemphigoid.

Report this publication

Statistics

Seen <100 times